Patrick Cabri

No ORCID on file · 6 papers in corpus
nonrandomized-trial 2023
Advances in therapy ·doi:10.1007/s12325-023-02617-8

INTRODUCTION: Triptorelin is available as 1- and 3-month prolonged-release (PR) formulations; at the time of the study, only the former was approved for central precocious puberty (CPP) in China. This study assessed the efficacy and safety …

rct 2022
Advances in therapy ·doi:10.1007/s12325-022-02264-5

INTRODUCTION: This phase 3, randomized, open-label, active-controlled, multicenter study investigated the efficacy of triptorelin pamoate prolonged-release (PR) 3-month in Chinese patients with endometriosis by demonstrating the noninferior…

2018
·doi:10.17116/rosakush201818272-82
observational 2018
·doi:10.17116/rosakush201818372-82

Popov А, Romanov V, Slobodyanyuk B, Maisonobe P, Cabri P, Chapron Ch. The clinical manifestations and anamnestic risk factors of different forms of endometriosis in Russian women: subgroup analyses in the framework of the international stud…

observational 2016
Advances in therapy ·doi:10.1007/s12325-016-0366-x

INTRODUCTION: The present study aimed to investigate clinical, lifestyle, and environmental factors associated with endometrioma (OMA) and/or deep infiltrating endometriosis (DIE) as determined by case-control comparison [women with superfi…

2015
·doi:10.5301/je.5000222

Purpose Endometriosis, a costly public health problem that is painful and impacts daily living and fertility, is poorly understood and managed. This study aimed to understand the impact of endometriosis on women from three culturally and ec…